

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 20, 2015.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *UMB Financial Corporation and Lakes Merger Sub LLC*, both in Kansas City, Missouri; to acquire 100 percent of the voting shares of Marquette Financial Companies, Minneapolis, Minnesota, parent of Meridian Bank, National Association, Phoenix, Arizona, and Meridian Bank Texas, Fort Worth, Texas. Immediately thereafter, Lakes Merger Sub LLC will merge into UMB Financial Corporation.

Board of Governors of the Federal Reserve System, March 20, 2015.

**Margaret McCloskey Shanks,**  
*Deputy Secretary of the Board.*

[FR Doc. 2015-06830 Filed 3-24-15; 8:45 am]

**BILLING CODE 6210-01-P**

**DEPARTMENT OF DEFENSE****GENERAL SERVICES ADMINISTRATION****NATIONAL AERONAUTICS AND SPACE ADMINISTRATION**

[OMB Control No. 9000-0054; Docket 2015-0053; Sequence 3]

**Federal Acquisition Regulation; Information Collection; U.S.-Flag Air Carriers Statement**

**AGENCIES:** Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA).

**ACTION:** Notice of request for public comments regarding an extension to an existing OMB clearance.

**SUMMARY:** Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat will be submitting to the Office of Management and Budget (OMB) a request to review and approve a previously approved information collection requirement concerning U.S. Flag Air Carriers Statement.

**DATES:** Submit comments on or before May 26, 2015.

**ADDRESSES:** Submit comments identified by Information Collection 9000-0054, U.S. Flag Air Carriers Statement by any of the following methods:

- *Regulations.gov:* <http://www.regulations.gov>. Submit comments via the Federal eRulemaking portal by searching the OMB control number 9000-0054. Select the link "Comment Now" that corresponds with "Information Collection "Information Collection 9000-0054, U.S. Flag Air Carriers Statement". Follow the instructions provided on the screen. Please include your name, company name (if any), and "Information Collection 9000-0054, U.S. Flag Air Carriers Statement" on your attached document.

- *Fax:* 202-501-4067.
- *Mail:* General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW., Washington, DC 20405. ATTN: Ms. Hada Flowers/IC 9000-0054, U.S. Flag Air Carriers Statement.

*Instructions:* Please submit comments only and cite Information Collection 9000-0054, U.S. Flag Air Carriers Statement, in all correspondence related to this collection. All comments received will be posted without change to <http://www.regulations.gov>, including any personal and/or business confidential information provided.

**FOR FURTHER INFORMATION CONTACT:** Mr. Curtis E. Glover, Sr. Procurement Analyst, Contract Policy Division, GSA 202-501-1448 or via email at [curtis.glover@gsa.gov](mailto:curtis.glover@gsa.gov).

**SUPPLEMENTARY INFORMATION:****A. Purpose**

Section 5 of the International Air Transportation Fair Competitive Practices Act of 1974 (49 U.S.C. 1517) (Fly America Act) requires that all Federal agencies and Government contractors and subcontractors at FAR 47.402, use U.S.-flag air carriers for U.S. Government-financed international air transportation of personnel (and their personal effects) or property, to the extent that service by those carriers is available. It requires the Comptroller General of the United States, in the absence of satisfactory proof of the necessity for foreign-flag air transportation, to disallow expenditures from funds, appropriated or otherwise established for the account of the United States, for international air transportation secured aboard a foreign-flag air carrier if a U.S.-flag air carrier is available to provide such services. In the event that the contractor selects a carrier other than a U.S.-flag air carrier for international air transportation during performance of the contract, the contractor shall include per FAR clause 52.247-64 a statement on vouchers involving such transportation. The contracting officer uses the information furnished in the statement to determine whether adequate justification exists for the contractor's use of other than a U.S.-flag air carrier.

**B. Annual Reporting Burden**

*Respondents:* 150.

*Responses per Respondent:* 2.

*Annual Responses:* 300.

*Hours per Response:* .25.

*Total Burden Hours:* 75.

**C. Public Comments**

Public comments are particularly invited on: Whether this collection of information is necessary for the proper performance of functions of the FAR, and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate, and based on valid assumptions and methodology; ways to enhance the quality, utility, and clarity of the information to be collected; and ways in which we can minimize the burden of the collection of information on those who are to respond, through the use of appropriate technological collection techniques or other forms of information technology.

**Obtaining Copies of Proposals:** Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat Division (MVCB), 1800 F Street NW., Washington, DC 20405, telephone 202-501-4755. Please cite OMB Control No. 9000-0054, Submission for OMB Review; U.S.-Flag Air Carriers Statement, in all correspondence.

Dated: March 19, 2015.

**Edward Loeb,**

*Acting Director, Office of Government-wide Acquisition Policy, Office of Acquisition Policy, Office of Government-wide Policy.*

[FR Doc. 2015-06818 Filed 3-24-15; 8:45 am]

**BILLING CODE 6820-EP-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Decision To Evaluate a Petition To Designate a Class of Employees From the Argonne National Laboratory-West in Scoville, Idaho, To Be Included in the Special Exposure Cohort

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** NIOSH gives notice of a decision to evaluate a petition to designate a class of employees from the Argonne National Laboratory-West in Scoville, Idaho, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000.

**FOR FURTHER INFORMATION CONTACT:** Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS C-46, Cincinnati, OH 45226-1938, Telephone 877-222-7570. Information requests can also be submitted by email to [DCAS@CDC.GOV](mailto:DCAS@CDC.GOV).

#### SUPPLEMENTARY INFORMATION:

**Authority:** 42 CFR 83.9-83.12.

Pursuant to 42 CFR 83.12, the initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

**Facility:** Argonne National Laboratory-West.

**Location:** Scoville, Idaho.

**Job Titles and/or Job Duties:** All workers who worked in any location.

**Period of Employment:** April 10, 1951 through December 31, 1979.

**John Howard,**

*Director, National Institute for Occupational Safety and Health.*

[FR Doc. 2015-06786 Filed 3-24-15; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** Technology descriptions follow.

#### Engineered Antibody Domains With Increased FcRn Binding and *in vivo* Half-Life

**Description of Technology:** Monoclonal antibodies (mAbs) are a fast growing class of new therapeutic molecules. However, their large size remains a significant challenge, preventing them from targeting sterically restricted epitopes and efficiently penetrating into tissues. Smaller antibody fragments and engineered variants are under development to address this challenge, but to date their therapeutic applications have been limited due to rapid clearance and short half-life which greatly decrease their efficacy *in vivo*.

This technology describes two antibody constant domains or binders with increased FcRn binding and *in vivo* half-life. In addition, these binders are small in size (16kDa), very stable, and can be efficiently expressed in *E. coli*. As a result, the binders are particularly well suited as scaffolds for the generation of antibody libraries, from which a desired antigen binders could be developed into therapeutic products with much greater potency compared to existing mAbs. They could also be used as fusion partners to extend the half-life of candidate protein therapeutics.

#### Potential Commercial Applications

- Antibody scaffolds for library construction, and the generation of therapeutics against various diseases.
- Fusion partners to extend the half-life of candidate protein therapeutics.

#### Competitive Advantages

- Small (16kD) size for better tissue penetration, and in the case of fusion proteins, reduced steric hindrance for therapeutic activity.
- Superior stability compared to isolated CH2 domains and stability comparable to or higher than that of an isolated Fc fragment.
- Exhibit greatly enhanced FcRn binding abilities, including more potent transcytosis and longer *in vivo* half-life.
- Can be efficiently expressed in *E. coli*.

#### Development Stage

- Early-stage
- *In vitro* data available
- *In vivo* data available (animal)

**Inventors:** Dimiter Dimitrov and Tianlei Ying (NCI).

**Intellectual Property:** HHS Reference No. E-136-2014/0—US Provisional Application No. 62/022,810 filed July 10, 2014.

**Licensing Contact:** Whitney Hastings, Ph.D.; 301-451-7337; [hastingw@mail.nih.gov](mailto:hastingw@mail.nih.gov).

**Collaborative Research Opportunity:** The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Engineered Antibody Domains. For collaboration opportunities, please contact John D. Hewes, Ph.D. at [john.hewes@nih.gov](mailto:john.hewes@nih.gov) or 240-276-5515.

#### CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells

**Description of Technology:** Methods of enhancing engraftment of donor hematopoietic stem cells (HSCs) by reducing expression or activity of